ID   A549 MX10
AC   CVCL_LB65
DR   cancercelllines; CVCL_LB65
DR   Wikidata; Q54607002
RX   PubMed=11406094;
RX   PubMed=11559526;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone.
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 22-08-17; Last updated: 05-10-23; Version: 10
//
RX   PubMed=11406094; DOI=10.1016/S0005-2736(01)00308-X;
RA   Robey R.W., Honjo Y., van de Laar A., Miyake K., Regis J.T.,
RA   Litman T., Bates S.E.;
RT   "A functional assay for detection of the mitoxantrone resistance
RT   protein, MXR (ABCG2).";
RL   Biochim. Biophys. Acta 1512:171-182(2001).
//
RX   PubMed=11559526;
RA   Honjo Y., Hrycyna C.A., Yan Q.-W., Medina-Perez W.Y., Robey R.W.,
RA   van de Laar A., Litman T., Dean M., Bates S.E.;
RT   "Acquired mutations in the MXR/BCRP/ABCP gene alter substrate
RT   specificity in MXR/BCRP/ABCP-overexpressing cells.";
RL   Cancer Res. 61:6635-6639(2001).
//